Skip to main content

Author: Linxi Mytkolli

Taking steps in the right direction to prevent diabetes-related amputation

That Dr. Charles de Mestral spent the morning before our interview at Queen’s Park advocating for improved wound care for people with diabetes in Ontario should not be surprising. The researcher and vascular surgeon at St. Michael’s Hospital has become a passionate voice for the need to stem the tide of amputations related to diabetes.

de Mestral, who is a Diabetes Action Canada researcher, recently co-led a study, published in the Canadian Medical Association Journal (CMAJ), that showed a rise in the number of diabetes-related lower limb amputations in Ontario. While this does correspond to the increasing number of type 2 diabetes diagnoses in the province, the results were still alarming.

“It’s discouraging,” says de Mestral, “because so many of those amputations could have been prevented. We know that [type 2] diabetes is increasing and that’s likely what’s driving this.” Part of the solution, he believes is to prevent diabetes and better control blood sugar in those living with the disease, but he also sees a need for improvements in foot care.

Unlike in other complications of diabetes, like eye disease or kidney damage, there is not always coordinated care of foot complications. Patients may not be able to access a chiropodist or podiatrist without paying additional fees and their family doctor may be too busy to provide the detailed regular foot care checks that Canadian and international guidelines recommended for patients with diabetes. This means that a patient may not get the care they need until far too late, when a wound that could easily have been treated requires a much more invasive approach.

For de Mestral, a vascular surgeon, a large part of his job is dealing with poor circulation in a patient’s legs. He estimates that he and his colleagues at St. Michael’s Hospital alone see a dozen patients a week with a limb-threatening problem, most often related to diabetes. “We know that in Canada over 80% of amputations are related to diabetes, often in conjunction with poor circulation, known as peripheral artery disease. And what I see too often is that patients are struggling to get the right care at the right time in order to prevent amputation. He is hopeful that by raising awareness among patients and scaling up the success of multi-disciplinary foot care teams involving doctors, podiatrists, chiropodists and nurses, diabetic foot ulcers can be diagnosed and treated earlier in order to ensure they heal properly, rather than result in amputation.

There is also a need to better understand the issues behind rising numbers of amputations and to develop an evidence-basis for prevention efforts across Canada. This is why the Government of Ontario recently awarded de Mestral an Early Researcher Award to support his work. “That award is allowing me to hire graduate students and other research team members to really focus on the problem of amputation in patients with diabetes and peripheral artery disease,” he says. “We’re first looking at better characterizing the burden of disease, with studies like the one that came out in CMAJ looking at rates of amputation over time in addition to identifying regions and patient groups with high rates of limb loss across the province.” de Mestral’s team will also be analyzing  the economic impact of amputation and  existing prevention efforts across the province in order to better understand where improvements can be made.

While he hopes to have an impact on patient lives through his research, de Mestral also knows that practical advice can be helpful for those living with diabetes who might be concerned about amputation risk. “The single most important message to anyone with diabetes is check your feet every day,” he says. “Or have a family member or caregiver help with this.” He suggests looking for wounds, redness, areas that might be tender or painful and discoloration of the toes – if you detect any of those things, go to your family doctor right away. “We know that people with diabetes have a 30% lifetime chance of getting a wound on their foot. Thankfully, and if a wound is recognized early, the chance of healing it is over 80%.”

Diabetes Canada offers a helpful checklist for those with diabetes to help support better foot care. You can access it on their website.

For more information about the work Diabetes Action Canada is doing in this area, visit the section of our website on Foot Care and Prevention of Amputation.

An economic analysis of the tele-retina screening program

Tele-retina Screening test being done on patient

 

The latest issue of the Canadian Journal of Ophthalmology features a paper from Diabetes Action Canada researcher Dr. Valeria Rac looking at the economic analysis of the tele-retina screening program for diabetic retinopathy.

Dr. Rac and her team concluded that this program is a more cost-effective means of screening for diabetic retinopathy than the current standard form of care for urban and rural individuals with diabetes who are at risk of being under-screened.

You can read the full paper on the Canadian Journal of Ophthalmology website.

Learn more about Diabetes Action Canada’s Tele-Retina Screening Program here.

 

Diabetes Action Canada is building a Digital Patient Engagement Network

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

Our Patient Partners, who live with T1D, have made it very clear that they feel disconnected from current clinical trials, researchers and research outcomes. In parallel, researchers struggle to connect with this diverse and geographically dispersed population. This disconnect is an impediment to recruitment to clinical trials and research, thereby hindering scientific advances that could greatly inform treatment pathways and improve health outcomes.

To bridge this gap, the Diabetes Action Canada iT1D Program is developing an opt-in digital platform for the purpose of recruiting, contacting and regularly engaging persons interested in contributing to clinical research to accelerating scientific advances that could greatly inform treatment pathways and improve health outcomes in T1D.  At time of registration those living with T1D will be asked to complete a very short questionnaire to determine their demographics, location and research interests as well as provide consent to be contacted for clinical research opportunities. Once enrolled, those living with T1D can explore clinical research opportunities and provide their opinion to help set targeted research priorities that address their specific needs.  Conversely, researchers will be able to directly engage members of the T1D Community in clinical research opportunities and in determining research questions for patient-oriented research projects.   To makes this platform truly patient-centred we have undergone an extensive co-design process with members of the T1D Community, which included large workshops with the T1D ThinkTank and Diabetes Action Canada Patient Partners, smaller working groups and one-on-one interviews.  This rigorous co-design has led us to a product that will present clinical research information in an easy to understand dashboard that presents information in a way that is easy to interpret and easy to determine if a clinical research study is a good match for the user.  The design of this digital patient engagement network, soon to be renamed, is nearly complete with an expected launch date in Q1 of 2020

Type 1 Diabetes TrialNet: A Type-1 Diabetes Research Network Screening Relatives of people with T1D and Innovative Clinical Studies

In our June 2019 newsletter we featured the ground-breaking news that the anti-CD3 antibody, Teplizumab, originally intended to protect new organs after kidney transplantation, could deactivate T cells that are targeting insulin producing beta cells.  This in turn could delay the onset of type-1 diabetes for those with close family members living with the condition.  What we didn’t mention was that those who participated in this study were recruited through the international research network called TrailNet.  TrialNet, funded by the National Institute for Health, offers risk screening for relatives of people living with type-1 diabetes and conducts innovative clinical studies to preserve insulin production.  The TrialNet Network includes 25 Clinical Centres and over 200 affiliated sites across North America, Europe, UK and Australia.  In Canada, the coordinating site operates out of the Hospital for Sick Children in Toronto and has 10 affiliated sites in Vancouver, Edmonton, Calgary, Winnipeg, London, Saskatchewan, Hamilton, Ottawa, Halifax and St. John’s.   Together these sites offer free Pathway to Prevention screening to evaluate the personal risk of developing T1D for relative of those living with the disease.   This minimally invasive blood test can detect autoantibodies that are predictive of developing T1D and those with these autoantibodies will have an opportunity to be monitored to ensure that if disease progression were to occur, that acute DKA and other complications are avoided.  Furthermore, those at risk of developing T1D can participate in prevention and insulin preservation trials to contribute to ground-breaking research, like the Teplizumab trial.  We are excited to be working collaboratively with TrialNet as Diabetes Action Canada develops our digital patient and researcher platform to connect those living with T1D with clinical research opportunities.  For more information on TrialNet you can visit their site here.

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

Tele-Retina Screening Program in the News

 

Tele-retina Screening test being done on patient

Recently, the Diabetes Action Canada Tele-Retina Screening Program was featured in the media.

Dr. Michael Brent was interviewed for a segment on CTV News specifically about this program. He also appeared on the Diabetes Canada Podcast to discuss this and other programs related to diabetic retinopathy research in Canada.

Diabetes Action Canada is working to prevent diabetic retinopathy, the leading cause of blindness in adults under 65 years of age, through accessible screening methods and advanced technology.

Learn more about our work in the area of diabetic retinopathy.

Watch the CTV News segment.

Listen to Dr. Michael Brent on the Diabetes Canada Podcast. 

 

 

Patient-Oriented Research in the Spotlight for Diabetes Awareness Month

Photos of Diabetes Action Canada Patient Partners

November is Diabetes Awareness Month, which is an opportunity for Diabetes Action Canada to highlight the organization’s work in developing patient- and research-informed health care delivery that is accessible to all and designed to prevent diabetes and its related complications.

Diabetes Action Canada is part of the Canadian Institutes for Health Research Strategic Patient-Oriented Research (SPOR) program dedicated to fully integrating patients into the health interventions research process.

“Researchers and health care professionals develop programs or strategies aimed at helping those living with diabetes, using all of their professional skills and knowledge. But, often, they fail to consider the realities of a day-to-day life with diabetes, which in turn leads to less impact for the project,” says Dr. Gary Lewis, Scientific Co-Lead at Diabetes Action Canada. “By incorporating the lived experience and opinions of patients who assist us in co-designing our research programs, we are able to develop solutions that meet the needs of the patient, address major barriers in access to health care, and improve the success of implementation.”

Diabetes Action Canada has developed multiple programs with their patient partners that demonstrate the value of this critically important collaboration in developing successful health care interventions.

“From increased access to screening for diabetic retinopathy (eye damage), to better support programs for seniors with diabetes, to improving the resilience and wellness of Indigenous youth to prevent diabetes, we have established understanding of how to better meet the needs of persons living with diabetes.” says Dr. Catharine Whiteside, Executive Director of Diabetes Action Canada. “Our mission is to improve patient experience, population outcomes and health professional experience, and to reduce health care costs related to diabetes.”

Diabetes Action Canada has so far supported more than 40 research projects, including:

  • The creation of the first National Diabetes Repository, a secure platform that contains anonymous information from more than 110,000 individuals with diabetes from several provinces. This repository allows researchers access to information that is used to investigate diabetes-related disease risk factors such as high blood pressure and high cholesterol, and design interventions to improve outcomes. There is no identifying information in the data, which is managed securely, and use is approved by a team of patient partners and health professionals who have set out specific guidelines for when and how this information can be used for research.
  • The ongoing development of a tele-retina screening program, which is designed to increase access to eye exams for people living with diabetes. This approach is proven effective and cost-effective for identifying previously undiagnosed, vision-threatening diabetes-related eye disease in high-risk populations who have been shown to have lower rates of screening. Early detection of diabetic retinopathy and treatment would eliminate diabetes as the number one cause of blindness in working age Canadians.
  • Research led by Diabetes Action Canada members showed an increase in diabetes-related amputations in Ontario over the last ten years. One of the most feared complications of diabetes is foot ulcers related to loss of nerve function and peripheral vascular disease, that could in some cases lead to limb amputation. Persons with diabetes want interventions that remove barriers and better support their day-to-day needs, including regular access to chiropodists to more effectively prevent and treat foot ulcers. The Diabetes Action Canada funded program makes this access possible—working with experts and patients to reduce amputation risk.

“Diabetes Action Canada has established a collaborative community with patient partners working directly with researchers and health professionals” says Whiteside.  “We anticipate outcomes that will transform the health trajectory for all Canadians with diabetes at risk for complications.”

Visit Diabetes Action Canada’s website and follow along on Twitter to learn more about these programs during Diabetes Awareness Month.

About Diabetes Action Canada

Diabetes Action Canada is a pan-Canadian research organization, launched in 2016, funded by the Canadian Institutes of Health Research’s Strategic Patient-Oriented Research program, non-profit organizations (e.g. Diabetes Canada, JDRF), and private sponsors, over 5 years. We focus on bringing patients, their caregivers and researchers together to identify the health concerns of those living with diabetes and to co-create research projects that address these concerns. We partner and collaborate with university research teams across Canada, non-profit organizations such as JDRF, and provincial governments to plan, execute and evaluate these research projects so we can improve patient outcomes and experiences.

Dr Charles De Mestral Receives an Ontario Early Career Researcher Award

Congratulations to Dr Charles de Mestral for being awarded an Ontario Early Researcher Award (ERA) for his proposal entitled: Regional Foot Core and Amputation Prevention Pathways For All Ontarians.

Dr. de Mestral is a Surgeon-scientist at St. Michael’s Hospital & Unity Health Toronto and an Assistant Professor of Surgery at the University of Toronto. The Early Researcher Awards program helps new researchers working at publicly funded Ontario research institutions, in a variety of academic fields, build their research teams. The program is funded by the Ontario Ministry of Economic Development, Job Creation and Trade. This award (S190,000 over 5 years) will support research on foot care and amputation prevention for people with diabetes or peripheral artery disease in Ontario.

The complete press release can be found  Here

Bourses de recherche postdoctorale du groupe de la formation et du mentorat du réseau Action diabète Canada 2019-2021

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

Au mois d’avril, le programme de la formation et du mentorat d’Action diabète Canada a lancé un nouveau concours de bourses postdoctorales. Huit demandes ont été reçues et un comité d’évaluation composé de chercheurs et de patients partenaires a été mise en place pour entamer le processus de sélection.Cette année, le groupe de la formation et du mentorat octroiera 4 bourses de recherche postdoctorale de 50 000 $ par an pour une période de deux ans. Nous sommes heureux d’annoncer les noms des récipiendaires des bourses du Concours de bourses de recherche postdoctorale 2019-2021.

Ruth Ndjaboue
Un programme de recherche à plusieurs volets, initié par le patient pour améliorer la communication des risques dans les soins du diabète – Université Laval, Superviseure : Holly Witteman; Co-superviseure : Sharon Straus

Bhavadharini Balaji
Explorer la faisabilité d’une application de santé mobile pour la gestion et le suivi des femmes atteintes de diabète sucré gestationnel (DSG) – Women’s College Research Institute, Women’s College Hospital, Superviseure : Lorraine Lipscombe

Radhouene Doggui
Évaluation de l’impact des systèmes de santé primaires sur la gestion à long terme du contrôle glycémique : une première étude longitudinale menée auprès de la population diabétique du Nouveau-Brunswick –  Centre de formation médicale du Nouveau-Brunswick, Superviseur : Mathieu BélangerSupervisor

Stephanie Read
Communication du risque de diabète de type 2 chez les femmes enceintes atteintes de diabète gestationnel – Women’s College Research Institute, Women’s College Hospital, Superviseure : Lorraine Lipscombe

Félicitations aux récipiendaires du groupe de la formation et du mentorat d’ADC et bon succès avec vos projets de recherche!

DAC Training and Mentorship Postdoctoral Fellowship Awards 2019-2021

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]
In April, the Diabetes Action Canada Training and Mentoring Program launched a new Postdoctoral Fellowship Competition. A total of 8 applications were received and an evaluation committee comprised of researchers and patient partners was assembled for the adjudication process.This year, the Training and Mentoring Group will be granting 4 Postdoctoral Fellowship Awards of $50,000/year for a period of two years. We are pleased to announce the successful recipients of the fellowship awards for this years’s Postdoctoral Fellowship Awards Competition 2019-2021

Ruth Ndjaboue
A multipronged, patient-initiated research program to improve risk communication in diabetes care – Université Laval, Supervisor: Holly Witteman; Co-supervisor Sharon Straus

Bhavadharini Balaji
Exploring the feasibility of a mobile health application for management and follow-up of women with gestational diabetes mellitus (GDM) – Women’s College Research Institute, Women’s College Hospital, Supervisor: Lorraine Lipscombe.

Radhouene Doggui
Assessment of primary healthcare systems impact on long-term management of glycemic control: A first longitudinal study conducted among New Brunswick diabetic population –  Centre de formation médicale du Nouveau-Brunswick, Supervisor: Mathieu Bélanger

Stephanie Read
Communicating type 2 diabetes risk in pregnant women with gestational diabetes – Women’s College Research Institute, Women’s College Hospital, Supervisor: Lorraine Lipscombe.

Congratulations to all the DAC Training and Mentoring Program Awardees and good luck with your research projects!

Revolutionize How we Use Health Data

[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]
[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

National Diabetes Repository

Diabetes Action Canada has successfully launched the first National Diabetes Repository in Canada.  This novel, secure analytics platform designed and implemented by Dr. Michelle Greiver (University of Toronto) and colleagues now contains information from over 110,000 individuals with diabetes in Alberta, Manitoba, Ontario, Newfoundland and Quebec, along with the same number of age-matched non-diabetic controls.  The National Diabetes Repository was created through collaboration with the Canadian Primary Care Sentinel Surveillance Network https://cpcssn.ca , using de-identified and encrypted primary care electronic medical records (EMRs) data that can be accessed by approved Diabetes Action Canada investigators for population-based and observational studies.  The repository has since evolved to accept patient reported outcomes and experience measures directly from patients using digital tablets that are directly connected to EMRs.  Data from provincial administrative data sources can be linked to individuals in each province to provide social determinants of health and outcomes data.  To facilitate data integration, data sharing agreements are anticipated with the provincial organization members of the SPOR National Data Platform research program.

In collaboration with the Fields Institute Centre for Quantitative Analysis and Modelling (Fields-CQAM), and the Vector Institute for Artificial Intelligence and investigators from the Dalla Lana School of Public Health from the University of Toronto, we held a two-day data workshop June 17th and 18th 2019.  Trainees and established researchers applied advanced analytics to the de-identified dataset within our National Diabetes Repository. The exercise provided much needed insights into the feasibility of using advanced mathematic modelling and artificial intelligence learning models on Canadian EMR data in a secure high-performance computing environment.  Using two testing environments, the results of this workshop showed that our data can be used for: 1) machine learning to predict patient responses to SGLT2 Inhibitors with high accuracy based on their health records; and, 2) artificial intelligence to identify the characteristics of sub-group patients, including their medication history, that are associated with different HbA1c trajectories.  Taken together, we were able to demonstrate that artificial intelligence and advanced analytics could be applied to our dataset to provide useful information for both patients and physicians in selecting treatment options to manage their condition.